Navigation Links
INVOcell Study Results to be Reported at the Annual Meeting of The American Society of Reproductive Medicine
Date:10/22/2010

DENVER and BEVERLY, Mass., Oct. 22 /PRNewswire/ -- INVO Bioscience, Inc. (OTC Bulltin Board: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, today announced that Dr. Elkin Lucena of the Columbian Fertility and Sterility Center (CECOFLES LTDA) will present the results of the first 95 fertility treatment cycles undertaken at the Center utilizing INVO Bioscience's INVOcell technology at the 66th Annual Meeting of the American Society for Reproductive Medicine on October 26, 2010 in Denver, Colorado.

The Annual Meeting of the American Society for Reproductive Medicine (ASRM) is one of the premier educational and professional networking conferences in the reproductive field. The theme for this year's event is "Taking Reproductive Medicine to New Heights." The event will feature a wide variety of postgraduate courses, lectures, symposia, roundtables, debates, abstracts, posters and videos focusing attention on the latest scientific developments in the field of reproductive medicine and their translation to clinical medicine.

Dr. Claude Ranoux, president of INVO Bioscience, commented, "We look forward with great anticipation to the CECOFLES presentation regarding the use of INVOcell in its initial treatment cycles. We are confident that INVOcell has performed well in these initial applications. Additionally, we are pleased that the study results have been accepted and will be unveiled at a prestigious conference the caliber of the ASRM."

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and earl
'/>"/>

SOURCE INVO Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NEW YORK , Sept. 17, 2014 /PRNewswire/ ... Summary GlobalData,s new report, "Germany ... market data on the Germany Gynecological Devices market. ... dollars, volume (in units) and average prices (in ... Devices (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization ...
(Date:9/17/2014)... SANTA MONICA, Calif. , Sept. 17, 2014 /PRNewswire-USNewswire/ ... who is at the White House today for National ... Proposition 46 that consumer advocates released today. Consumer advocates ... woman who spoke out after losing her ... later discovering that the doctor had a history of ...
(Date:9/17/2014)... , Sept. 17, 2014  Decision ... colitis (CD/UC) patients eligible for biologic therapy, ... a biologic. Surveyed gastroenterologists cite patients, discomfort ... for low penetration rates, followed by cost-related ... UC patients receiving biologics, Janssen Biotech,s Remicade ...
Breaking Medicine Technology:Germany Gynecological Devices Market Outlook to 2020 2Germany Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3
... OncoSec Medical Incorporated (OTCBB:ONCS), which is developing ... to treat solid tumor cancers, today announced that ... and Lakeland Comprehensive Cancer Center in Lakeland, FL ... are screening patients for the Phase II metastatic ...
... International, Inc. (NASDAQ: BDSI ) announced that ... of further litigation in the patent infringement lawsuit previously ... that the case would be stayed pending resolution by ... proceedings and follows the recent rejection by the USPTO ...
Cached Medicine Technology:OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 2OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 3OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial 4Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 2Federal Court Grants Request by BioDelivery Sciences for Stay of MonoSol Litigation 3
(Date:9/18/2014)... N-Zyme Scientifics LLC achieved a major ... product a mere 8 months after company startup. Its ... glycan release enzyme used in the “Biologics” industry for ... for tissue pathology on Mass Spec devices. PRIME™ is ... North American market (PNGase F PRIMETM). N-Zyme is ...
(Date:9/17/2014)... Recently, BambooIndustry.com, an outstanding company in the ... floorings . There are more than 1000 items in this ... big promotion for these useful items. Each of them is ... , “We are very proud to unveil the new ... these items are made with natural materials by experienced workers. ...
(Date:9/17/2014)... 18, 2014 Recently, UWDress.com, an innovative ... women’s special occasion outfits, has released its 2014 ... the firm has launched a big sale for these ... available at deeply discounted rates, from 15 to 65 ... company insists on using comfortable to wear materials. Its ...
(Date:9/17/2014)... September 18, 2014 Dr. Shalev is a ... to Houston to study at the University of Texas, and ... studying she realized her real passion lay in dentistry, and ... from the University of Texas Health Science Center at Houston ... and is a member of The Greater Houston Dental Society, ...
(Date:9/17/2014)... 18, 2014 The National Resident Matching ... , a comprehensive analysis of the relationship between unique ... specialty. The new edition is based on the ... for U.S. allopathic medical school senior students and all ... able to provide this new edition of Charting Outcomes ...
Breaking Medicine News(10 mins):Health News:N-Zyme Scientifics Announces Successful Product Launch 2Health News:More Than 1000 Items Added To BambooIndustry.com’s Bamboo Flooring Collection 2Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 2Health News:Just Released: Charting Outcomes in the Match for the 2014 Main Residency Match® 3
... 5 (HealthDay News) -- Giving antibiotics to pregnant women at ... newborns, according to a new study. Use of antibiotics ... and should also be used in developing countries, at least ... Edmond, of the London School of Hygiene and Tropical Medicine ...
... WASHINGTONThe rezoning around a planned light rail line in the ... the health of the people in the communities it would ... today by PolicyLink, TakeAction Minnesota, and ISAIAH, a nonprofit coalition ... Paul and St. Cloud region. The HIA was made possible ...
... Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- A vaccine ... severe liver damage and even liver cancer, might be possible ... , There is currently no vaccine for hepatitis C, which ... HIV, the hepatitis C virus mutates easily and has always ...
... HealthDay Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- ... United States in recent years are charted in a new report. ... by 1.8 percent a year in men and 1.6 percent a ... And from 1990 through 2008, death rates plunged almost 23 percent ...
... quality of life higher in cancer survivors who exercise, ... though most doctors recommend exercise, many patients fail ... University of Colorado Cancer Center, recently published in the ... by the American College of Sports Medicine, makes planning ...
... The rotovirus vaccine was pulled from the marketplace in ... the updated rotavirus vaccines do not appear to increase ... to a new study by child health experts at ... of the vaccine,re-introduced in 2006 and 2008, prevent infection ...
Cached Medicine News:Health News:Antibiotics in Pregnancy May Shield Newborns From Strep B 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 2Health News:Twin Cities light rail project presents both opportunities and risks for health, according to report 3Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3Health News:Cancer Incidence, Death Rates Continue to Drop: Report 2Health News:Cancer Incidence, Death Rates Continue to Drop: Report 3Health News:Downloadable tool helps cancer survivors plan and monitor exercise 2Health News:U-M study shows updated rotavirus vaccine not linked to increase in bowel obstruction 2